+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Global Meningococcal Vaccine Market By Brand, By Type, By Age Group, By Region, Industry Analysis and Forecast, 2020 - 2026

  • ID: 5241474
  • Report
  • January 2021
  • Region: Global
  • 201 pages
  • Marqual IT Solutions Pvt. Ltd (KBV Research)

FEATURED COMPANIES

  • Bio-Med Pvt. Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Sanofi S.A.
The Global Meningococcal Vaccine Market size is expected to reach $4.5 billion by 2026, rising at a market growth of 8.5% CAGR during the forecast period. Meningococcal meningitis is a bacterial infection that is caused by gram-negative bacteria, Neisseria meningitides that includes a spectrum of infections such as bacteremia (meningococcemia), meningitis, and bacteremia pneumonia.

The meningococcal disease is very rare but is highly fatal, if left untreated, up to 50% of the patients die or get some serious complications thereafter. In meningococcal meningitis, bacteria infect the lining of the brain and spinal cord and can potentially cause large endemics as well as epidemics. The disease is transmitted from an infected person through direct contact with droplets of the throat or respiratory secretions, asymptomatic carriers can also capable of transmitting infection.

There is an increasing prevalence of various types of bacteria that cause meningococcal meningitis. The most common type of meningitis causing bacteria are A, B, C, W, Y, and type X that was more lately reported in Africa, continue to underline the criticality of more effective vaccine of meningococcal to be available in the coming years.

Over the past few decades, cases of meningitis have been increased and are one of the key factors likely to drive the market for meningococcal vaccines. According to the Centers for Disease Control and Prevention (CDC), about 1.2 million cases of meningococcal meningitis are estimated to occur worldwide every year. The government and regulatory authorities are taking initiatives to combat the increasing prevalence of meningitis are likely to drive the market growth. For example, “Defeating meningitis by 2030” was introduced in 2018 at the World Health Assembly by Eastern Mediterranean and African regions. This program is focused to develop a strategic roadmap for the prevention of meningitis by prioritizing research and improved control activities.



By Brand

Based on Brand, the market is segmented into Bexsero, Trumenba, Nimenrix, Menactra, Menveo and Other Brands. The MenACWY vaccine and MenC vaccine are expected to experience swift growth during the forecast period. This is accredited to the increased adoption of these vaccines in several countries across the globe through immunization programs. Furthermore, outbreaks of meningococcal in several countries resulted in an increasing demand for meningococcal vaccines, which further boost the growth of the meningococcal vaccine market.

By Type

Based on Type, the market is segmented into Bivalent, Quadrivalent and Other Types. Quadrivalent meningococcal vaccines had the largest revenue share of the market in 2019, owing to the increased used brands like Menveo, Menactra, and Nimenrix, for this category. New vaccines are increasingly approved that will protect people against meningococcal meningitis and is expected to boost the growth of this market.



By Age Group

Based on Age Group, the market is segmented into Infants (0 to 2 years) and Children (2 years & above). The infant segment is anticipated to be the fastest-growing segment in the coming years due to the increasing incidence of meningitis among infants. According to the European Centre for Disease Prevention and Control (ECDC), IMD incidence was observed highest in infants in 2017. In Europe, there were nearly 8.2 confirmed cases per 100,000 populations in children below one year.

By Region

Based on Regions, the market is segmented into North America, Europe, Asia Pacific, and Latin America, Middle East & Africa. North America led the market and had a significant revenue share of the market in 2019 which is followed by Europe. Favorable approvals, supportive initiatives by the government, and high investments in R&D are the major factors fueling the North American market.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include GlaxoSmithKline PLC (GSK), Pfizer, Inc., Sanofi S.A., Walvax Biotechnology Co., Ltd., Bio-Manguinhos (Oswaldo Cruz Foundation), Bio-Med Pvt. Ltd., Chongqing Zhifei Biological Products Co., Ltd., Hualan Biological Engineering, Inc., Incepta Pharmaceuticals Ltd. and Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.).

Strategies deployed in Meningococcal Vaccine Market

Dec-2020: Serum Institute of India (SII) launched world's most affordable pneumococcal conjugate vaccine (PCV) in India. This vaccine provides protection against 10 variants of pneumococcus bacteria that causes pneumonia, meningitis, ear, and blood infections in children.

Dec-2020: The Oswaldo Cruz Foundation, through the Institute of Technology in Immunobiologicals (Bio-Manguinhos) announced an agreement with the Government of the State of Rio de Janerio. Following this agreement, the Industrial Complex of Biotechnology in Health (Cibs) will be built, in the Industrial District of Santa Cruz, in Rio de Janeiro. The new plant aims to enable the production of new vaccines, such as the bivalent vaccine (measles and rubella), clinical studies of which were recently concluded by Bio-Manguinhos, and meningococcal C, which is in an advanced stage of studies phases II/III, in addition to new vaccine presentations from the Institute's portfolio (number of doses/bottle), to meet different needs of the health system.

Nov-2020: Sanofi's MenQuadfi received approval from The European Commission (EC) for active immunization of individuals from the age of 12 months and older against invasive meningococcal disease. This disease is caused by Neisseria meningitidis serogroups A, C, W and Y. The MenQuadfi has been delivering optimized stability while maintaining the vaccine in a convenient, fully liquid presentation. Apr-2018: Pfizer's TRUMENBA (Meningococcal Group B Vaccine) received approval from the U.S. Food and Drug Administration (FDA). This vaccine is being used for active immunization for preventing invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years.

Apr-2020: MenQuadfi, Meningococcal (Groups A, C, Y, W) Conjugate Vaccine received Biologics License Application approval from FDA. This vaccine has been used for the prevention of invasive meningococcal disease in persons 2 years of age and older.

Feb-2018: GlaxoSmithKline announced that it received Breakthrough Therapy Designation from FDA for its meningitis B vaccine Bexsero for developing vaccine in the prevention of Invasive Meningococcal Disease (IMD) caused by serogroup B in children 2-10 years of age.

May-2017: Pfizer announced that European Commission approved TRUMENBA (Meningococcal Group B Vaccine). This vaccine aimed to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroup B (MenB) in individuals 10 years of age and older.

Dec-2016: Pfizer got approval from European Commission for Nimenrix (meningococcal group A, C, W-135, and Y conjugate vaccine). This vaccine was developed for active immunization against invasive meningococcal disease (IMD) caused by Neisseria meningitidis serogroups A, C, W-135, and Y (MenACWY) in infants as early as six weeks of age.

Scope of the Study

Market Segments covered in the Report:

By Brand
  • Bexsero
  • Trumenba
  • Nimenrix
  • Menactra
  • Menveo
  • Other Brands
By Type
  • Bivalent
  • Quadrivalent
  • Other Types
By Age Group
  • Infants (0 to 2 years)
  • Children (2 years & above)
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Sanofi S.A.
  • Walvax Biotechnology Co., Ltd.
  • Bio-Manguinhos (Oswaldo Cruz Foundation)
  • Bio-Med Pvt. Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • Incepta Pharmaceuticals Ltd.
  • Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Unique Offerings from the Publisher
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Bio-Med Pvt. Ltd.
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Sanofi S.A.
Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Meningococcal Vaccine Market, by Brand
1.4.2 Global Meningococcal Vaccine Market, by Type
1.4.3 Global Meningococcal Vaccine Market, by Age Group
1.4.4 Global Meningococcal Vaccine Market, by Geography
1.5 Methodology for the research

Chapter 2. Market Overview
2.1 Introduction
2.1.1 Overview
2.1.2 Market composition and scenario
2.2 Key Factors Impacting the Market
2.2.1 Market Drivers
2.2.2 Market Restraints

Chapter 3. Recent Developments in Meningococcal Vaccine Market

Chapter 4. Global Meningococcal Vaccine Market by Brand
4.1 Global Bexsero Market by Region
4.2 Global Trumenba Market by Region
4.3 Global Nimenrix Market by Region
4.4 Global Menactra Market by Region
4.5 Global Menveo Market by Region
4.6 Global Other Brands Market by Region

Chapter 5. Global Meningococcal Vaccine Market by Type
5.1 Global Bivalent Market by Region
5.2 Global Quadrivalent Market by Region
5.3 Global Other Types Market by Region

Chapter 6. Global Meningococcal Vaccine Market by Age Group
6.1 Global Children (2 years & above) and Adults Market by Region
6.2 Global Infants(0 to 2 years) Market by Region

Chapter 7. Global Meningococcal Vaccine Market by Region
7.1 North America Meningococcal Vaccine Market
7.1.1 North America Meningococcal Vaccine Market by Brand
7.1.1.1 North America Bexsero Market by Country
7.1.1.2 North America Trumenba Market by Country
7.1.1.3 North America Nimenrix Market by Country
7.1.1.4 North America Menactra Market by Country
7.1.1.5 North America Menveo Market by Country
7.1.1.6 North America Other Brands Market by Country
7.1.2 North America Meningococcal Vaccine Market by Type
7.1.2.1 North America Bivalent Market by Country
7.1.2.2 North America Quadrivalent Market by Country
7.1.2.3 North America Other Types Market by Country
7.1.3 North America Meningococcal Vaccine Market by Age Group
7.1.3.1 North America Children (2 years & above) and Adults Market by Country
7.1.3.2 North America Infants(0 to 2 years) Market by Country
7.1.4 North America Meningococcal Vaccine Market by Country
7.1.4.1 USA Meningococcal Vaccine Market
7.1.4.1.1 USA Meningococcal Vaccine Market by Brand
7.1.4.1.2 USA Meningococcal Vaccine Market by Type
7.1.4.1.3 USA Meningococcal Vaccine Market by Age Group
7.1.4.2 Canada Meningococcal Vaccine Market
7.1.4.2.1 Canada Meningococcal Vaccine Market by Brand
7.1.4.2.2 Canada Meningococcal Vaccine Market by Type
7.1.4.2.3 Canada Meningococcal Vaccine Market by Age Group
7.1.4.3 Mexico Meningococcal Vaccine Market
7.1.4.3.1 Mexico Meningococcal Vaccine Market by Brand
7.1.4.3.2 Mexico Meningococcal Vaccine Market by Type
7.1.4.3.3 Mexico Meningococcal Vaccine Market by Age Group
7.1.4.4 Rest of North America Meningococcal Vaccine Market
7.1.4.4.1 Rest of North America Meningococcal Vaccine Market by Brand
7.1.4.4.2 Rest of North America Meningococcal Vaccine Market by Type
7.1.4.4.3 Rest of North America Meningococcal Vaccine Market by Age Group
7.2 Europe Meningococcal Vaccine Market
7.2.1 Europe Meningococcal Vaccine Market by Brand
7.2.1.1 Europe Bexsero Market by Country
7.2.1.2 Europe Trumenba Market by Country
7.2.1.3 Europe Nimenrix Market by Country
7.2.1.4 Europe Menactra Market by Country
7.2.1.5 Europe Menveo Market by Country
7.2.1.6 Europe Other Brands Market by Country
7.2.2 Europe Meningococcal Vaccine Market by Type
7.2.2.1 Europe Bivalent Market by Country
7.2.2.2 Europe Quadrivalent Market by Country
7.2.2.3 Europe Other Types Market by Country
7.2.3 Europe Meningococcal Vaccine Market by Age Group
7.2.3.1 Europe Children (2 years & above) and Adults Market by Country
7.2.3.2 Europe Infants(0 to 2 years) Market by Country
7.2.4 Europe Meningococcal Vaccine Market by Country
7.2.4.1 Germany Meningococcal Vaccine Market
7.2.4.1.1 Germany Meningococcal Vaccine Market by Brand
7.2.4.1.2 Germany Meningococcal Vaccine Market by Type
7.2.4.1.3 Germany Meningococcal Vaccine Market by Age Group
7.2.4.2 UK Meningococcal Vaccine Market
7.2.4.2.1 UK Meningococcal Vaccine Market by Brand
7.2.4.2.2 UK Meningococcal Vaccine Market by Type
7.2.4.2.3 UK Meningococcal Vaccine Market by Age Group
7.2.4.3 France Meningococcal Vaccine Market
7.2.4.3.1 France Meningococcal Vaccine Market by Brand
7.2.4.3.2 France Meningococcal Vaccine Market by Type
7.2.4.3.3 France Meningococcal Vaccine Market by Age Group
7.2.4.4 Russia Meningococcal Vaccine Market
7.2.4.4.1 Russia Meningococcal Vaccine Market by Brand
7.2.4.4.2 Russia Meningococcal Vaccine Market by Type
7.2.4.4.3 Russia Meningococcal Vaccine Market by Age Group
7.2.4.5 Spain Meningococcal Vaccine Market
7.2.4.5.1 Spain Meningococcal Vaccine Market by Brand
7.2.4.5.2 Spain Meningococcal Vaccine Market by Type
7.2.4.5.3 Spain Meningococcal Vaccine Market by Age Group
7.2.4.6 Italy Meningococcal Vaccine Market
7.2.4.6.1 Italy Meningococcal Vaccine Market by Brand
7.2.4.6.2 Italy Meningococcal Vaccine Market by Type
7.2.4.6.3 Italy Meningococcal Vaccine Market by Age Group
7.2.4.7 Rest of Europe Meningococcal Vaccine Market
7.2.4.7.1 Rest of Europe Meningococcal Vaccine Market by Brand
7.2.4.7.2 Rest of Europe Meningococcal Vaccine Market by Type
7.2.4.7.3 Rest of Europe Meningococcal Vaccine Market by Age Group
7.3 Asia Pacific Meningococcal Vaccine Market
7.3.1 Asia Pacific Meningococcal Vaccine Market by Brand
7.3.1.1 Asia Pacific Bexsero Market by Country
7.3.1.2 Asia Pacific Trumenba Market by Country
7.3.1.3 Asia Pacific Nimenrix Market by Country
7.3.1.4 Asia Pacific Menactra Market by Country
7.3.1.5 Asia Pacific Menveo Market by Country
7.3.1.6 Asia Pacific Other Brands Market by Country
7.3.2 Asia Pacific Meningococcal Vaccine Market by Type
7.3.2.1 Asia Pacific Bivalent Market by Country
7.3.2.2 Asia Pacific Quadrivalent Market by Country
7.3.2.3 Asia Pacific Other Types Market by Country
7.3.3 Asia Pacific Meningococcal Vaccine Market by Age Group
7.3.3.1 Asia Pacific Children (2 years & above) and Adults Market by Country
7.3.3.2 Asia Pacific Infants(0 to 2 years) Market by Country
7.3.4 Asia Pacific Meningococcal Vaccine Market by Country
7.3.4.1 China Meningococcal Vaccine Market
7.3.4.1.1 China Meningococcal Vaccine Market by Brand
7.3.4.1.2 China Meningococcal Vaccine Market by Type
7.3.4.1.3 China Meningococcal Vaccine Market by Age Group
7.3.4.2 India Meningococcal Vaccine Market
7.3.4.2.1 India Meningococcal Vaccine Market by Brand
7.3.4.2.2 India Meningococcal Vaccine Market by Type
7.3.4.2.3 India Meningococcal Vaccine Market by Age Group
7.3.4.3 Japan Meningococcal Vaccine Market
7.3.4.3.1 Japan Meningococcal Vaccine Market by Brand
7.3.4.3.2 Japan Meningococcal Vaccine Market by Type
7.3.4.3.3 Japan Meningococcal Vaccine Market by Age Group
7.3.4.4 South Korea Meningococcal Vaccine Market
7.3.4.4.1 South Korea Meningococcal Vaccine Market by Brand
7.3.4.4.2 South Korea Meningococcal Vaccine Market by Type
7.3.4.4.3 South Korea Meningococcal Vaccine Market by Age Group
7.3.4.5 Singapore Meningococcal Vaccine Market
7.3.4.5.1 Singapore Meningococcal Vaccine Market by Brand
7.3.4.5.2 Singapore Meningococcal Vaccine Market by Type
7.3.4.5.3 Singapore Meningococcal Vaccine Market by Age Group
7.3.4.6 Malaysia Meningococcal Vaccine Market
7.3.4.6.1 Malaysia Meningococcal Vaccine Market by Brand
7.3.4.6.2 Malaysia Meningococcal Vaccine Market by Type
7.3.4.6.3 Malaysia Meningococcal Vaccine Market by Age Group
7.3.4.7 Rest of Asia Pacific Meningococcal Vaccine Market
7.3.4.7.1 Rest of Asia Pacific Meningococcal Vaccine Market by Brand
7.3.4.7.2 Rest of Asia Pacific Meningococcal Vaccine Market by Type
7.3.4.7.3 Rest of Asia Pacific Meningococcal Vaccine Market by Age Group
7.4 LAMEA Meningococcal Vaccine Market
7.4.1 LAMEA Meningococcal Vaccine Market by Brand
7.4.1.1 LAMEA Bexsero Market by Country
7.4.1.2 LAMEA Trumenba Market by Country
7.4.1.3 LAMEA Nimenrix Market by Country
7.4.1.4 LAMEA Menactra Market by Country
7.4.1.5 LAMEA Menveo Market by Country
7.4.1.6 LAMEA Other Brands Market by Country
7.4.2 LAMEA Meningococcal Vaccine Market by Type
7.4.2.1 LAMEA Bivalent Market by Country
7.4.2.2 LAMEA Quadrivalent Market by Country
7.4.2.3 LAMEA Other Types Market by Country
7.4.3 LAMEA Meningococcal Vaccine Market by Age Group
7.4.3.1 LAMEA Children (2 years & above) and Adults Market by Country
7.4.3.2 LAMEA Infants(0 to 2 years) Market by Country
7.4.4 LAMEA Meningococcal Vaccine Market by Country
7.4.4.1 Brazil Meningococcal Vaccine Market
7.4.4.1.1 Brazil Meningococcal Vaccine Market by Brand
7.4.4.1.2 Brazil Meningococcal Vaccine Market by Type
7.4.4.1.3 Brazil Meningococcal Vaccine Market by Age Group
7.4.4.2 Argentina Meningococcal Vaccine Market
7.4.4.2.1 Argentina Meningococcal Vaccine Market by Brand
7.4.4.2.2 Argentina Meningococcal Vaccine Market by Type
7.4.4.2.3 Argentina Meningococcal Vaccine Market by Age Group
7.4.4.3 UAE Meningococcal Vaccine Market
7.4.4.3.1 UAE Meningococcal Vaccine Market by Brand
7.4.4.3.2 UAE Meningococcal Vaccine Market by Type
7.4.4.3.3 UAE Meningococcal Vaccine Market by Age Group
7.4.4.4 Saudi Arabia Meningococcal Vaccine Market
7.4.4.4.1 Saudi Arabia Meningococcal Vaccine Market by Brand
7.4.4.4.2 Saudi Arabia Meningococcal Vaccine Market by Type
7.4.4.4.3 Saudi Arabia Meningococcal Vaccine Market by Age Group
7.4.4.5 South Africa Meningococcal Vaccine Market
7.4.4.5.1 South Africa Meningococcal Vaccine Market by Brand
7.4.4.5.2 South Africa Meningococcal Vaccine Market by Type
7.4.4.5.3 South Africa Meningococcal Vaccine Market by Age Group
7.4.4.6 Nigeria Meningococcal Vaccine Market
7.4.4.6.1 Nigeria Meningococcal Vaccine Market by Brand
7.4.4.6.2 Nigeria Meningococcal Vaccine Market by Type
7.4.4.6.3 Nigeria Meningococcal Vaccine Market by Age Group
7.4.4.7 Rest of LAMEA Meningococcal Vaccine Market
7.4.4.7.1 Rest of LAMEA Meningococcal Vaccine Market by Brand
7.4.4.7.2 Rest of LAMEA Meningococcal Vaccine Market by Type
7.4.4.7.3 Rest of LAMEA Meningococcal Vaccine Market by Age Group

Chapter 8. Company Profiles
8.1 GlaxoSmithKline PLC (GSK)
8.1.1 Company Overview
8.1.2 Financial Analysis
8.1.3 Segmental and Regional Analysis
8.1.4 Research & Development Expense
8.1.5 Recent strategies and developments:
8.1.5.1 Approvals:
8.2 Pfizer, Inc.
8.2.1 Company Overview
8.2.1 Financial Analysis
8.2.2 Segmental and Regional Analysis
8.2.3 Recent strategies and developments:
8.2.3.1 Approvals:
8.3 Sanofi S.A.
8.3.1 Company Overview
8.3.2 Financial Analysis
8.3.3 Segmental and Regional Analysis
8.3.4 Research & Development Expense
8.3.5 Recent strategies and developments:
8.3.5.1 Approvals:
8.4 Walvax Biotechnology Co., Ltd.
8.4.1 Company Overview
8.5 Bio-Manguinhos (Oswaldo Cruz Foundation)
8.5.1 Company Overview
8.5.2 Recent strategies and developments:
8.5.2.1 Partnerships, Collaborations, and Agreements:
8.6 Bio-Med Pvt. Ltd.
8.6.1 Company Overview
8.7 Chongqing Zhifei Biological Products Co., Ltd.
8.7.1 Company Overview
8.8 Hualan Biological Engineering, Inc.
8.8.1 Company Overview
8.9 Incepta Pharmaceuticals Ltd.
8.9.1 Company Overview
8.10. Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
8.10.1 Company Overview
8.10.2 Recent strategies and developments:
8.10.2.1 Product Launches and Product Expansions:
Note: Product cover images may vary from those shown
  • GlaxoSmithKline PLC (GSK)
  • Pfizer, Inc.
  • Sanofi S.A.
  • Walvax Biotechnology Co., Ltd.
  • Bio-Manguinhos (Oswaldo Cruz Foundation)
  • Bio-Med Pvt. Ltd.
  • Chongqing Zhifei Biological Products Co., Ltd.
  • Hualan Biological Engineering, Inc.
  • Incepta Pharmaceuticals Ltd.
  • Serum Institute of India Pvt. Ltd. (Poonawalla Investments & Industries Pvt. Ltd.)
Note: Product cover images may vary from those shown

Loading
LOADING...

Adroll
adroll